The data pertaining to the COVID‐19 pandemic has been rapidly evolving since the first confirmed case in December 2019. This review article presents a comprehensive analysis of the current data in relation to COVID‐19 and its effect on pregnant women, including symptoms, disease severity and the risk of vertical transmission. We also review the recommended management of pregnant women with suspected or confirmed COVID‐19 and the various pharmacological agents that are being investigated and may have a role in the treatment of this disease. At present, it does not appear that pregnant women are at increased risk of severe infection than the general population, although there are vulnerable groups within both the pregnant and nonpregnant populations, and clinicians should be cognizant of these high‐risk groups and manage them accordingly. Approximately 85% of women will experience mild disease, 10% more severe disease and 5% critical disease. The most common reported symptoms are fever, cough, shortness of breath and diarrhea. Neither vaginal delivery nor cesarean section confers additional risks, and there is minimal risk of vertical transmission to the neonate from either mode of delivery. We acknowledge that the true effect of the virus on both maternal and fetal morbidity and mortality will only be evident over time. We also discuss the impact of social isolation can have on the mental health and well‐being of both patients and colleagues, and as clinicians, we must be mindful of this and offer support as necessary.

What is already known on this topic? Parents are willing to use pharmacies as an alternative to clinics for their children's vaccination services, including the human papillomavirus (HPV) vaccine. However, the willingness of pharmacists to administer or promote this vaccine, especially in rural areas, is not well understood. What is added by this report? Rural pharmacists have the potential to be effective collaborators for HPV vaccine administration and promotion, but barriers, such as lack of education and capacity, exist. What are the implications for public health practice? Barriers to using pharmacists as providers of HPV vaccine could be overcome through partnerships with stakeholders who are already promoting the administration of HPV vaccine, and these barriers should be the focus of future research.

No abstract

Type of publicationArticle (peer-reviewed) A detailed experimental study of antiphase dynamics in a two-mode semiconductor laser with optical injection is presented. The device is a specially designed Fabry-Pérot laser that supports two primary modes with a terahertz frequency spacing. Injection in one of the primary modes of the device leads to a rich variety of single and two-mode dynamical scenarios, which are reproduced with remarkable accuracy by a fourdimensional rate equation model. Numerical bifurcation analysis reveals the importance of torus bifurcations in mediating transitions to antiphase dynamics and of saddle node of limit-cycle bifurcations in switching of the dynamics between single-and two-mode regimes.